No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 9.0x · 10Y median 9.6x · 45th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:01:39.381Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for C4 Therapeutics, Inc. (CCCC) stock was $2.86 as of Oct 6, 2026, 12:55 PM EDT, down 4.35% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +31.6% · 3-year avg +22.2%/yr · 5-year avg -41.8%/yr
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates.
Biotechnology · Watertown, MA
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.20
Revenue Est.
$8.82M
Last Quarter Results
EPS
$-0.18
vs Estimate
$-0.23
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CCCC | $315.67M | $2.85 | -4.52% | +31.55% | -41.77% | N/A | N/A |
| 2SMTI | $321.61M | $34.98 | -0.04% | +12.15% | +0.35% | +24.23% | vs CCCC |
| 3RCEL | $321.93M | $12.96 | -2.20% | +138.18% | -5.28% | +4.36% | vs CCCC |
| 4CLPT | $322.39M | $10.75 | -6.68% | -57.75% | -7.65% | +6.57% | vs CCCC |
| 5CABA | $323.66M | $1.99 | -4.57% | -14.69% | -28.71% | N/A | vs CCCC |
| 6CV | $323.73M | $6.48 | -1.60% | +37.37% | N/A | N/A | vs CCCC |
forward FY estimate
N/A
$6.64M
vs Estimate
$4.00M
Consensus Rating
Based on 6 analysts
Average Price Target
$13.33
+367.0% upside
Low
$7.00
Current
$2.85
High
$30.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.21 | $-0.20 | $-0.19 | 3 |
| Quarter ending Dec 2026 | $-0.33 | $-0.29 | $-0.24 | 3 |
| Quarter ending Mar 2027 | $-0.27 | $-0.27 | $-0.27 | 1 |
| Quarter ending Jun 2027 | $-0.23 | $-0.23 | $-0.23 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.92 | $-0.87 | $-0.82 | 4 |
| FY 2027 | $-1.04 | $-0.96 | $-0.88 | 4 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $8.82M | $8.82M | $8.82M | 3 |
| Quarter ending Dec 2026 | $4.00M | $4.00M | $4.00M | 3 |
| Quarter ending Mar 2027 | $5.00M | $5.00M | $5.00M | 1 |
| Quarter ending Jun 2027 | $5.00M | $5.00M | $5.00M | 1 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $18.81M | $25.66M | $34.58M | 3 |
| FY 2027 | $15.03M | $20.50M | $27.63M | 3 |
